Cargando…

GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery

Glycopeptide antibiotics (GPAs) are essential for the treatment of severe infectious diseases caused by Gram-positive bacteria. The emergence and spread of GPA resistance have propelled the search for more effective GPAs. Given their structural complexity, genetic intractability, and low titer, expa...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Min, Wang, Wenliang, Waglechner, Nicholas, Culp, Elizabeth J., Guitor, Allison K., Wright, Gerard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567792/
https://www.ncbi.nlm.nih.gov/pubmed/33067466
http://dx.doi.org/10.1038/s41467-020-19138-5
_version_ 1783596396763414528
author Xu, Min
Wang, Wenliang
Waglechner, Nicholas
Culp, Elizabeth J.
Guitor, Allison K.
Wright, Gerard D.
author_facet Xu, Min
Wang, Wenliang
Waglechner, Nicholas
Culp, Elizabeth J.
Guitor, Allison K.
Wright, Gerard D.
author_sort Xu, Min
collection PubMed
description Glycopeptide antibiotics (GPAs) are essential for the treatment of severe infectious diseases caused by Gram-positive bacteria. The emergence and spread of GPA resistance have propelled the search for more effective GPAs. Given their structural complexity, genetic intractability, and low titer, expansion of GPA chemical diversity using synthetic or medicinal chemistry remains challenging. Here we describe a synthetic biology platform, GPAHex (GPA Heterologous expression), which exploits the genes required for the specialized GPA building blocks, regulation, antibiotic transport, and resistance for the heterologous production of GPAs. Application of the GPAHex platform results in: (1) a 19-fold increase of corbomycin titer compared to the parental strain, (2) the discovery of a teicoplanin-class GPA from an Amycolatopsis isolate, and (3) the overproduction and characterization of a cryptic nonapeptide GPA. GPAHex provides a platform for GPA production and mining of uncharacterized GPAs and provides a blueprint for chassis design for other natural product classes.
format Online
Article
Text
id pubmed-7567792
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75677922020-10-19 GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery Xu, Min Wang, Wenliang Waglechner, Nicholas Culp, Elizabeth J. Guitor, Allison K. Wright, Gerard D. Nat Commun Article Glycopeptide antibiotics (GPAs) are essential for the treatment of severe infectious diseases caused by Gram-positive bacteria. The emergence and spread of GPA resistance have propelled the search for more effective GPAs. Given their structural complexity, genetic intractability, and low titer, expansion of GPA chemical diversity using synthetic or medicinal chemistry remains challenging. Here we describe a synthetic biology platform, GPAHex (GPA Heterologous expression), which exploits the genes required for the specialized GPA building blocks, regulation, antibiotic transport, and resistance for the heterologous production of GPAs. Application of the GPAHex platform results in: (1) a 19-fold increase of corbomycin titer compared to the parental strain, (2) the discovery of a teicoplanin-class GPA from an Amycolatopsis isolate, and (3) the overproduction and characterization of a cryptic nonapeptide GPA. GPAHex provides a platform for GPA production and mining of uncharacterized GPAs and provides a blueprint for chassis design for other natural product classes. Nature Publishing Group UK 2020-10-16 /pmc/articles/PMC7567792/ /pubmed/33067466 http://dx.doi.org/10.1038/s41467-020-19138-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Xu, Min
Wang, Wenliang
Waglechner, Nicholas
Culp, Elizabeth J.
Guitor, Allison K.
Wright, Gerard D.
GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery
title GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery
title_full GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery
title_fullStr GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery
title_full_unstemmed GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery
title_short GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery
title_sort gpahex-a synthetic biology platform for type iv–v glycopeptide antibiotic production and discovery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567792/
https://www.ncbi.nlm.nih.gov/pubmed/33067466
http://dx.doi.org/10.1038/s41467-020-19138-5
work_keys_str_mv AT xumin gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery
AT wangwenliang gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery
AT waglechnernicholas gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery
AT culpelizabethj gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery
AT guitorallisonk gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery
AT wrightgerardd gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery